Corline Biomedical (IZ7) Stock Overview

Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. More details

IZ7 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 47.31% per year

Risk Analysis

Earnings have declined by 41.3% per year over past 5 years

Does not have a meaningful market cap (€42M)

Does not have meaningful revenue (SEK11M)

IZ7 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW482,538 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

482,538 investors already sharing narratives

View all narratives

Corline Biomedical AB Competitors

Price History & Performance

Summary of share price highs, lows and changes for Corline Biomedical
Historical stock prices
Current Share Price	SEK 1.55
52 Week High	SEK 1.72
52 Week Low	SEK 1.34
Beta	0.32
1 Month Change	-0.32%
3 Month Change	9.15%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	6.16%

Recent updates

Shareholder Returns

	IZ7	DE Pharmaceuticals	DE Market
7D	-1.9%	-1.1%	0.5%
1Y	n/a	35.1%	-0.9%

Return vs Industry: Insufficient data to determine how IZ7 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how IZ7 performed against the German Market.

Price Volatility

Is IZ7's price volatile compared to industry and market?
IZ7 volatility
IZ7 Average Weekly Movement	6.5%
Pharmaceuticals Industry Average Movement	6.0%
Market Average Movement	5.4%
10% most volatile stocks in DE Market	12.5%
10% least volatile stocks in DE Market	2.6%

Stable Share Price: IZ7 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine IZ7's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1991	13	Henrik Nittmar	www.corline.se

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company’s products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. It offers CHS stent, a metallic tube-shaped device for the treatment of acute or threatened vessel closure during coronary angioplasty; CHS Coated Ablation Catheter to treat heart arrythmia; Renaparin for use in the treatment of end stage renal failure; and CHC, which is used for the treatment of soft tissue injuries.

Corline Biomedical AB Fundamentals Summary

How do Corline Biomedical's earnings and revenue compare to its market cap?
IZ7 fundamental statistics
Market cap	€41.63m
Earnings (TTM)	-€1.28m
Revenue (TTM)	€965.49k

43.1x

P/S Ratio

-32.5x

P/E Ratio

Is IZ7 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IZ7 income statement (TTM)
Revenue	SEK 10.67m
Cost of Revenue	SEK 1.83m
Gross Profit	SEK 8.83m
Other Expenses	SEK 22.98m
Earnings	-SEK 14.14m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.54
Gross Margin	82.81%
Net Profit Margin	-132.61%
Debt/Equity Ratio	0%

How did IZ7 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/24 04:03
End of Day Share Price	2026/07/24 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Corline Biomedical AB is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Gustaf Meyer	Redeye

Corline Biomedical ABDB:IZ7 Stock Report